<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A low level of <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>) is a key feature of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi> particles exert an anti-atherogenic effect, and low <z:chebi fb="0" ids="47775">HDL-C</z:chebi> levels are associated with increased <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risk </plain></SENT>
<SENT sid="2" pm="."><plain>The profile of <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> sub-classes may also be abnormal in patients with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, with an excess of atherogenic small <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) particles </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="35664">Statins</z:chebi> are first-line <z:chebi fb="23" ids="18059">lipid</z:chebi>-modifying drugs that, in addition to varying in their effects on <z:chebi fb="0" ids="47774">LDL-C</z:chebi>, differ in their effects on <z:chebi fb="0" ids="47775">HDL-C</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="38545">Rosuvastatin</z:chebi> has been shown to be at least as effective at increasing <z:chebi fb="0" ids="47775">HDL-C</z:chebi> compared with <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, pravastatin or <z:chebi fb="0" ids="9150">simvastatin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Selecting an agent that will increase <z:chebi fb="0" ids="47775">HDL-C</z:chebi> levels, as well as lowering <z:chebi fb="0" ids="47774">LDL-C</z:chebi> levels, may be particularly beneficial in the treatment of patients with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>